Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.
The canarypox vaccine vector (ALVAC) technology has been used to develop and license several vaccines for companion animals and horses in the European Union and USA. ALVAC is a ubiquitous vector with high biosafety since it is non-replicative in mammalians, is genetically and physically stable, and able to induce both humoral and cell-mediated immune responses against the expressed transgene product. Specific rules apply for the development and registration of recombinant vector vaccines. The biology of the vector as well as the recombinant virus must be thoroughly documented to allow the risk assessment of its use in the target species. In particular, its safety for the host and the environment must be extensively demonstrated before field trials can be authorized.
Poulet
Hervé
H
Merial SAS, 254, rue Marcel Mérieux, 69007 Lyon, France. herve.poulet@merial.com
Minke
Jules
J
Pardo
Maria Camila
MC
Juillard
Véronique
V
Nordgren
Bob
B
Audonnet
Jean-Christophe
JC
D000818:Animals; D028121:Canarypox virus / Q000235:genetics*; D017277:Drug Approval; D005822:Genetic Vectors / Q000235:genetics*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D014765:Viral Vaccines / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*
D014614:Vaccines, Synthetic; D014765:Viral Vaccines